- Home
- RXT vs DNA Comparison
RXT vs DNA Comparison
Compare RXT & DNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RXT
- DNA
- Stock Information
- Founded
- RXT 1998
- DNA 2008
- Country
- RXT United States
- DNA United States
- Employees
- RXT N/A
- DNA N/A
- Industry
- RXT EDP Services
- DNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RXT Technology
- DNA Health Care
- Exchange
- RXT Nasdaq
- DNA Nasdaq
- Market Cap
- RXT N/A
- DNA 466.4M
- IPO Year
- RXT 2020
- DNA N/A
- Fundamental
- Price
- RXT $1.44
- DNA $7.87
- Analyst Decision
- RXT Sell
- DNA Sell
- Analyst Count
- RXT 2
- DNA 5
- Target Price
- RXT $1.65
- DNA $17.25
- AVG Volume (30 Days)
- RXT 701.5K
- DNA 1.3M
- Earning Date
- RXT 05-08-2025
- DNA 05-06-2025
- Dividend Yield
- RXT N/A
- DNA N/A
- EPS Growth
- RXT N/A
- DNA N/A
- EPS
- RXT N/A
- DNA N/A
- Revenue
- RXT $2,737,100,000.00
- DNA $237,417,000.00
- Revenue This Year
- RXT N/A
- DNA N/A
- Revenue Next Year
- RXT $1.73
- DNA $16.74
- P/E Ratio
- RXT N/A
- DNA N/A
- Revenue Growth
- RXT N/A
- DNA 13.76
- 52 Week Low
- RXT $1.24
- DNA $5.00
- 52 Week High
- RXT $3.41
- DNA $38.60
- Technical
- Relative Strength Index (RSI)
- RXT 45.91
- DNA 54.95
- Support Level
- RXT $1.37
- DNA $6.42
- Resistance Level
- RXT $1.45
- DNA $7.71
- Average True Range (ATR)
- RXT 0.08
- DNA 0.62
- MACD
- RXT 0.04
- DNA 0.01
- Stochastic Oscillator
- RXT 65.52
- DNA 70.73
About DNA Ginkgo Bioworks Holdings Inc.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering: where company provide biological R&D services for customers across a range of industries and Biosecurity: where it provide services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.